Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for Plantar Fasciitis
NCT02973269Phase 2Terminated
- Sponsor
- Revance Therapeutics
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plantar fasciitis comparing DAXI 240 U with Placebo (2 arms). Primary endpoint: American Orthopaedic Foot and Ankle Score at 16 weeks. Started Nov 2016; status: terminated.
02
Drugs
daxibotulinumtoxinA
03
Conditions
plantar fasciitis
Beyond the preview
Go deeper on NCT02973269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973269.